Veflox Indications/Uses

Veflox is indicated for the treatment of adults with mild, moderate, and severe infections caused by susceptible strains of the designated microorganisms in the conditions listed as follows.
Acute sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.
Acute exacerbation of chronic bronchitis due to Staphylococus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophillus parainfluenzae or Moraxella catarrhalis.
Community-acquired pneumonia due to Staphylococcus aureus, Streptococcus pneumoniae (including penicillin-resistant strains), Haemophilus influenzae, Heamophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pheumoniae, Legionella pneumophila or Mycoplasma pneumoniae.
Nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended.
Uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections due to Staphylococcus aureus and Streptococcus pyogenes.
Complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes or Proteus mirabilis.
Complicated urinary tract infections due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa or Staphylococcus saprophyticus.
Chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or Staphylococcus epidermidis.
Acute pyelonephritis caused by Escherichia coli.
750 mg: Empirical treatment for community acquired pneumonia most likely caused by organisms susceptible to levofloxacin.
Third-line therapy for Helicobacter pylori Infection: Levofloxacin-based Triple Therapy: Levofloxacin, in combination with other antimicrobial agent and proton pump inhibitor as triple therapy, is indicated for the treatment of patients with gastric ulcer caused by Helicobacter pylori infection and duodenal ulcer disease.